methods.Depressive symptoms were measured using the Montgomery-sberg Depression Rating Scale (MADRS) at baseline, after each treatment day, and at 1-and 4-week follow-up visits.Eight participants have been enrolled to date with a target enrollment of 25 participants.Results: Preliminary findings from the first 8 participants (mean age=21, SD=4.3) indicate both promising clinical response and good tolerability.Baseline MADRS mean score of 38 (SD=4) decreased to 13 (SD=9) by Day 5 (66% reduction), with 5 out of 6 participants achieving remission-level scores (MADRS 10) at 1month follow-up.Columbia Suicide Severity Rating Scale (C-SSRS) scores decreased from a mean of 14.5 (SD=1.1) to 6.8 (SD=2.7)(68% reduction).Accelerated iTBS was well tolerated, with only mild to moderate symptoms, most commonly fatigue and sleepiness, and no serious adverse events or treatment discontinuations.Discussion: Overall, preliminary data suggests early signals of efficacy of aiTBS for treatment of depression in adolescents and young adults.Establishing the feasibility of this treatment may support broader adoption of aiTBS as a rapid intervention for highrisk youth.
Eide et al. (Mon,) studied this question.